Clinical trials: Treatment naïve
Rheumatoid Arthritis
Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients
Is pneumococcal conjugate vaccine (which induces a T-dependent humoral response) more efficient than pneumococcal polysaccharide vaccine (which induces a T-independent humoral response) in RA patients treated with abatacept…
- Trial name
- VACINA (NCT02547493)
- Testing
- pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, Abatacept
- Where
- 11 sites in France, Monaco
- Volunteers
- 80 people
- Sponsor
- University Hospital, Montpellier
Paroxysmal Nocturnal Hemoglobinuria
Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients
The aim of this non-interventional secondary use of data study is to evaluate hematological response in patients with paroxysmal nocturnal hemoglobinuria and anemia in the 6-month period after initiation of anti-C5 antibody…
- Trial name
- APPEX (NCT05842486)
- Testing
- Anti-C5 antibody treatment
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pancreatic Cancer
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
- Trial name
- NCT06941857
- Testing
- Oxaliplatin, Irinotecan, Folinic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Infection, Human Immunodeficiency Virus, HIV Infections
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine…
- Trial name
- NCT01910402
- Testing
- Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir
- Where
- 90 sites in United States, Argentina and 11 more
- Volunteers
- 499 people
- Sponsor
- ViiV Healthcare
Cholangiocarcinoma
Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma
The purpose of this study is to determine whether everolimus is effective in the treatment of patients with advance cholangiocarcinoma.
- Trial name
- CRAD001T (NCT01525719)
- Testing
- Everolimus
- Volunteers
- 40 people
- Sponsor
- Ratchavithi Hospital
Lung Adenocarcinoma Metastatic
Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma
Background: While third-generation EGFR tyrosine kinase inhibitors (TKI) like aumolertinib have significantly improved outcomes for patients with advanced lung adenocarcinoma, those harboring the L858R mutation still experience…
- Trial name
- NCT07624487
- Testing
- Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin)
- Where
- 3 sites in Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Medical University Hospital
Lung Cancer, NSCLC
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily.
- Conditions
- Lung Cancer, NSCLC, Brain Metastases
- Trial name
- DURABLE (NCT05987644)
- Testing
- Alectinib, Stereotactic Radiosurgery
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Joshua Palmer
Glioblastoma, Glioma
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-naïve patients…
- Conditions
- Glioblastoma, Glioma, Neoplasms, Neuroepithelial, Neuroectodermal Tumors
- Trial name
- NCT04388033
- Testing
- Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12, Temozolomide
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HIV-1 Infection
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
This study was done to see if the combination of two anti-HIV medicines, dolutegravir (DTG, Tivicay) and lamivudine (3TC, Epivir) taken once a day, provide a safe, effective, and well-tolerated treatment for HIV.
- Trial name
- NCT02582684
- Testing
- Dolutegravir, Lamivudine
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 122 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Chronic Hepatitis C
Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM
Peg interferon and ribavirin currently represent the standard approved association for treating patients infected with hepatitis C virus (HCV) .
- Trial name
- CINAM (NCT00199719)
- Testing
- Ribavirine
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Limoges
HIV, HIV Infections
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir…
- Trial name
- NCT01780506
- Testing
- E/C/F/TAF, E/C/F/TDF
- Where
- 117 sites in United States, Australia and 10 more
- Volunteers
- 872 people
- Sponsor
- Gilead Sciences
Hypercholesterolemia
Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects
The purpose of this study is to evaluate the low density lipoprotein cholesterol (LDL-C) lowering effect of Bococizumab (PF-04950615;RN316) administered subcutaneously at every two weeks (Q14D) in hypercholesterolemic Japanese…
- Trial name
- NCT02055976
- Testing
- Bococizumab (PF-04950615;RN316), Ezetimibe
- Where
- 9 sites in Japan
- Volunteers
- 218 people
- Sponsor
- Pfizer
Lymphocytic Leukemia, Chronic
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
This study will evaluate the efficacy and safety of intense combination treatment including MabThera/Rituxan (rituximab), followed by MabThera/Rituxan maintenance therapy in patients with B-cell CLL who are naive to chemotherapy.
- Trial name
- NCT02013817
- Testing
- rituximab [MabThera/Rituxan], fludarabine, cyclophosphamide
- Where
- 8 sites in Austria
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Lantus Versus Levemir Treat-To-Target
Primary objective: To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not…
- Trial name
- L2T3 (NCT00405418)
- Testing
- Insulin glargine, Insulin Detemir
- Where
- 20 sites in Australia, Brazil and 18 more
- Volunteers
- 973 people
- Sponsor
- Sanofi
Hepatitis C Virus
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than…
- Trial name
- HEPCAT (NCT01125189)
- Testing
- Daclatasvir, peg-interferon alfa-2a, ribavirin
- Where
- 64 sites in United States, Australia and 9 more
- Volunteers
- 558 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Cancer
FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study
This study aims to answer very important questions regarding the prevalence of somatic and germline mutations (sBRCAm and gBRCAm) in a population of newly diagnosed ovarian cancer patients from Latin America.
- Trial name
- FLABRA (NCT02984423)
- Where
- 27 sites in Argentina, Brazil and 4 more
- Volunteers
- 471 people
- Sponsor
- AstraZeneca
Diabetic Macular Edema
A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor…
- Trial name
- ALTIMETER (NCT04597918)
- Testing
- Faricimab
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Wet Age-related Macular Degeneration
Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients
The purpose of this observational study lies in the analysis of a treat-and-extend injection scheme with intravitreal aflibercept (i.e.
- Trial name
- ASTERIA (NCT03382587)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Switzerland
- Volunteers
- 163 people
- Sponsor
- Bayer
Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic
To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients
A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection.
- Conditions
- Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis, Treatment naïve
- Trial name
- NCT03593447
- Testing
- non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin, non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin, non-cirrhotic subjects. low TG-2349+ low DAG181
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Colorectal Cancer
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
The purpose of this study is to investigate biomarkers which may be predictors of efficacy and safety of treatment with mFOLFOX6 + bevacizumab versus mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naïve unresectable…
- Trial name
- NCT02394834
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
- Where
- 151 sites in Japan
- Volunteers
- 757 people
- Sponsor
- Takeda